Andrea Pfeifer, AC Immune CEO
How do you put a positive spin on ugly data? AC Immune gives it a shot in the wake of the latest crenezumab flop
Researchers spent close to a decade looking for signs that the failed Alzheimer’s drug crenezumab might work in a study that restricted itself to a …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
